Nuevolution AB (publ) intends to move the listing of its shares to Nasdaq Stockholm’s main market during the fiscal year 2017/18
Stockholm, 18 September 2017 -- Nuevolution AB (publ), a leading small-molecule drug-discovery biotech company listed on Nasdaq Stockholm First North Premier (NUE.ST), today announced that the company intends to move the listing of its shares to the Nasdaq Stockholm’s main market in fiscal 2017/18. Following a review of Nuevolution’s business strategy, the Board of Directors is of the opinion that the time is appropriate to move the listing of the Company’s shares to a regulated market. This forms an important part of the Company’s strategy “Grand plan - Reaching New Horizons”. ‘The